Logo image
Engineering nanoallergens to investigate origins of immunogenicity and cross-reactivity in cephalosporin allergy
Journal article   Peer reviewed

Engineering nanoallergens to investigate origins of immunogenicity and cross-reactivity in cephalosporin allergy

Emily K. Bromley, Jenna N. Sjoerdsma, Caitlin L. Horgan, Scott A. Smith, David A. Khan, Elizabeth J. Phillips, Kimberly G. Blumenthal, Cosby A. Stone and Basar Bilgicer
Journal of allergy and clinical immunology, Vol.155(6), pp.1957-1967
2025
PMID: 40020935

Abstract

Allergy Immunology Life Sciences & Biomedicine Science & Technology
Background: A major obstacle to the effective diagnosis of cephalosporin allergies is that the haptens, or segments of their molecular structures, which are responsible for the initiation of an immunogenic response, are unknown. Objective: This study aimed to identify immunogenic moieties of cefazolin to accurately predict IgE-mediated allergy and cross-reactivity with other cephalosporin antibiotics. Methods: Hapten immunogenicity analysis is performed using liposomal nanoallergens integrated in a cellular degranulation assay to quantify secreted allergic mediators. RBL-SX38 cells were primed with purified human monoclonal IgE or patient plasma samples before nanoallergen challenge. The monoclonal IgE priming consisted of dust mite-or peanut-specific negative controls and were compared against a cefazolin-specific monoclonal IgE. The plasma samples, in contrast, came from 3 drug allergy-negative control patients, or 2 cefazolin-allergic patients who provided 3 samples. Results: Multiple forms of cefazolin are immunogenic when multivalently presented by nanoallergens, and there may be alternate nanoparticle formulations that can effectively diagnose IgE-mediated cefazolin allergy in patients. Additionally, common R1 or R2 groups in cephalosporin molecular structures do not singularly identify shared crossreactivity. Conclusion: This study highlights an innovative method to reproducibly distinguish cefazolin-allergic from nonallergic patients using finely tuned cefazolin-hapten-presenting nanoallergens in conjunction with an in vitro cellular degranulation assay.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#9 Industry, Innovation and Infrastructure

Source: SDGs in the Output

Metrics

1 Record Views
Logo image